35100
document
Intravenous or intramuscular teicoplanin once daily for skin and soft-tissue infections . Teicoplanin is a new glycopeptide antibiotic with potent activity against gram-positive bacteria and pharmacokinetics that allow once daily administration . To study the efficacy and safety of teicoplanin for skin and soft-tissue infections , 75 patients received teicoplanin intravenously ( 38 ) or intramuscularly ( 37 , of which 16 were outpatients ) . Of 62 clinically evaluable patients , 97 percent of teicoplanin iv and 93 percent of teicoplanin im patients were cured or improved . All teicoplanin iv patients and 64 percent of teicoplanin im patients were cured microbiologically at 24-48 hours posttherapy . Persistence of organisms frequently was associated with skin ulcers or abscess cavities and usually had no bearing on clinical outcome . Possible adverse clinical and laboratory reactions caused by teicoplanin occurred in 4 of 38 teicoplanin iv patients ( 11 percent ) and in 8 of 37 teicoplanin im patients ( 22 percent ) . Reactions were mild and resolved with discontinuation of teicoplanin in most cases . In this study , teicoplanin appeared to be safe , efficacious , and convenient for both hospital staff and patients , and potentially cost-effective for the treatment of skin and soft-tissue infections . In particular , teicoplanin appears to be appropriate for outpatient parenteral therapy .
35101
Intervention_Pharmacological
Intravenous or intramuscular teicoplanin
35102
Intervention_Pharmacological
Teicoplanin
35103
Intervention_Pharmacological
teicoplanin
35104
Intervention_Pharmacological
teicoplanin intravenously ( 38 ) or intramuscularly
35105
Intervention_Pharmacological
teicoplanin
35106
Intervention_Pharmacological
teicoplanin
35107
Intervention_Pharmacological
teicoplanin
35108
Intervention_Pharmacological
teicoplanin
35109
Intervention_Pharmacological
teicoplanin
35110
Intervention_Pharmacological
teicoplanin
35111
Intervention_Pharmacological
teicoplanin
35112
Intervention_Pharmacological
teicoplanin
35113
Outcome_Physical
skin and soft-tissue infections
35114
Outcome_Other
efficacy and safety
35115
Outcome_Physical
cured microbiologically
35116
Outcome_Physical
skin ulcers or abscess cavities
35117
Outcome_Adverse-effects
adverse clinical and laboratory reactions
35118
Outcome_Adverse-effects
mild
35119
Outcome_Other
safe , efficacious , and convenient
35120
Outcome_Other
cost-effective
35121
Participant_Condition
skin and soft-tissue infections
35122
Participant_Sample-size
75
35123
Participant_Sample-size
62 clinically evaluable patients